Skip to Content

Zirgan Approval History

FDA Approved: Yes (First approved September 15, 2009)
Brand name: Zirgan
Generic name: ganciclovir
Dosage form: Ophthalmic Gel
Company: Sirion Therapeutics, Inc.
Treatment for: Keratitis

Zirgan (ganciclovir ophthalmic gel) is a topical ophthalmic antiviral preparation for the treatment of acute herpetic keratitis (dendritic ulcers).

Development History and FDA Approval Process for Zirgan

DateArticle
Sep 16, 2009Approval Sirion Therapeutics Announces FDA Approval of Zirgan (ganciclovir ophthalmic gel) 0.15% for Herpetic Keratitis
Jan 26, 2009Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide